-
[show abstract]
[hide abstract]
ABSTRACT: A series of inhibitors of d-amino acid oxidase (DAAO) are specific in blocking chronic pain, including formalin-induced tonic pain, neuropathic pain and bone cancer pain. This study used RNA interference technology to further validate the notion that spinal DAAO mediates formalin-induced pain. To target DAAO, a siRNA/DAAO formulated in polyetherimide (PEI) complexation and a shRNA/DAAO (shDAAO, with the same sequence as siRNA/DAAO after intracellular processing) expressed in recombinant adenoviral vectors were designed. The siRNA/DAAO was effective in blocking DAAO expression in NRK-52E rat kidney tubule epithelial cells, compared to the nonspecific oligonucleotides. Furthermore, multiple-daily intrathecal injections of both siRNA/DAAO and Ad-shDAAO for 7 days significantly inhibited spinal DAAO expression by 50-80% as measured by real-time quantitative PCR and Western blot, and blocked spinal DAAO enzymatic activity by approximately 60%. Meanwhile, both siRNA/DAAO and Ad-shDAAO prevented formalin-induced tonic phase pain by approximately 60%. Multiple-daily intrathecal injections of siRNA/DAAO and Ad-shDAAO also blocked more than 30% spinal expression of GFAP, a biomarker for the activation of astrocytes. These results further suggest that down-regulation of spinal DAAO expression and enzymatic activity leads to analgesia with its mechanism potentially related to activation of astrocytes in the spinal cord.
Biochemical and Biophysical Research Communications 04/2012; 421(3):501-7. · 2.48 Impact Factor
-
[show abstract]
[hide abstract]
ABSTRACT: Scandinavian Journal of Pain j o u r n a l h o m e p a g e : w w w . S c a n d i n a v i a n J o u r n a l P a i n . c o m a b s t r a c t Background: Sleep deprivation as well as peripheral neuropathy and cutaneous neurogenic inflammation has a facilitatory effect on pain perception. Here we studied whether oxidative stress-related mechanisms in the spinal cord that have been shown to contribute to pain facilitation in peripheral neuropathy and cutaneous neurogenic inflammation play a role in sleep deprivation-induced pain hypersensitivity. Methods: Flower pot method was used to induce rapid eye movement sleep deprivation (REMSD) of 48 h duration in the rat that had a chronic intrathecal (i.t.) catheter for spinal administration of drugs. Pain behavior was assessed by determining the monofilament-induced limb withdrawal response. Results: REMSD of 48 h produced mechanical hypersensitivity that was attenuated in a dose-related fashion by i.t. administration of two different antioxidants, phenyl-N-tert-butylnitrone (PBN) or 4-hydroxy-2,2,6,6-tetramethylpiperidine-1 oxyl (TEMPOL). While both antioxidants attenuated mechan-ical pain behavior also in control animals, their effects were significantly stronger after REMSD than in control conditions. Conversely, i.t. administration of a reactive oxygen species (ROS) donor, tert-butyl-hydroperoxide (t-BOOH), in control animals produced pain hypersensitivity that was prevented by i.t. pretreatment with an antioxidant, TEMPOL. I.t. treatment with PBN or TEMPOL at the currently used doses failed to influence motor behavior in the Rotarod test. Conclusions: The results indicate that among common mechanisms contributing to mechanical pain hypersensitivity following sleep deprivation as well as nerve injury or neurogenic inflammation is oxida-tive stress in the spinal cord. Implications: Compounds with antioxidant properties might prove useful in suppressing the vicious pronociceptive interaction between chronic pain and sleep-deprivation.
Journal of Pain. 01/2011; 2:64-69.
-
[show abstract]
[hide abstract]
ABSTRACT: We studied the hypothesis that some of the spinal mechanisms that are involved in neuropathic hypersensitivity play a role in hypersensitivity induced by REM sleep deprivation (REMSD). Rats with a chronic intrathecal (i.t.) catheter had REMSD of 48h duration that induced hypersensitivity to mechanical stimulation. After REMSD, the animals were treated i.t. with carbenoxolone (a gap junction decoupler), bumetanide (a blocker of Na(+)-K(+)-2Cl(-) cotransporter 1 or NKCC1), muscimol (a GABA(A) receptor agonist), or pretreated intraperitoneally with minocycline (an inhibitor of microglia activation). Previously, all these treatments attenuated neuropathic hypersensitivity. Following REMSD, carbenoxolone, bumetanide and muscimol had a strong antihypersensitivity effect, whereas pretreatment with minocycline failed to prevent development of hypersensitivity. The results suggest that among spinal pain facilitatory mechanisms that are common to REMSD and neuropathy are NKCC1 blocker- and gap junction decoupler-reversible mechanisms. Moreover, there is a net pain inhibitory effect by spinal administration of an exogenous GABA(A) receptor agonist following REMSD as shown earlier in neuropathy. In contrast, activation of spinal microglia may not be as important for the development of hypersensitivity induced by REMSD as following nerve injury.
Pharmacology Biochemistry and Behavior 12/2010; 97(2):377-83. · 2.53 Impact Factor
-
[show abstract]
[hide abstract]
ABSTRACT: We have found that mutation of D-amino acid oxidase (DAO) diminished formalin-induced tonic pain. The present research further studied the analgesic effects of a series of DAO inhibitors in this model. 5-Chlorobenzo[d]isoxazol-3-ol (CBIO), 4H-thieno[3,2-b]pyrrole-5-carboxylic acid (compound 8), 5-methylpyrazole-3-carboxylic acid (AS057278), sodium benzoate, and 4-nitro-3-pyrazole carboxylic acid (NPCA) inhibited rat spinal cord-derived DAO activity in a concentration-dependent manner, with maximal inhibition of 100% and potency rank of CBIO > compound 8 > AS057278 > sodium benzoate > NPCA. In rats, intrathecal injections of CBIO, compound 8, AS057278, and sodium benzoate but not NPCA specifically prevented formalin-induced tonic pain but not acute nociception, with the same potency order as in the DAO activity assay. The highly potent analgesia of DAO inhibitors was evidenced by CBIO, which prevented 50% pain at 0.06 μg, approximately 5-fold the potency of morphine. CBIO given after formalin challenge also reversed the established pain state to the same degree as prevention. The antihyperalgesic potencies of these DAO inhibitors were highly correlated to their inhibitions of spinal DAO activity. Maximum inhibition of pain by these compounds was approximately 60%, comparable with that of the N-methyl-D-aspartic acid receptor antagonist (+)-5-methyl-10,11-dihydro-5H-dibenzo[a,d]cyclohepten-5,10-imine maleate (MK-801), suggesting that a larger portion of formalin-induced tonic pain is "DAO-sensitive," whereas the remaining 40% of tonic pain and acute nociception is "DAO-insensitive." These findings, combined with our previous DAO gene mutation and induction results, indicate spinal DAO mediates both induction and maintenance of formalin-induced tonic pain and further validate spinal DAO as a novel and efficacious target molecule for the treatment of chronic pain.
Journal of Pharmacology and Experimental Therapeutics 10/2010; 336(1):282-93. · 3.83 Impact Factor
